01 May 2004
Drug monitoring of pyrimethamine during maintenance therapy of toxoplasmic encephalitis in patients with advanced HIV infection during HAART
Peter Langmann, Michael Zilly, Diana Schirmer, Hartwig KlinkerMed Sci Monit 2004; 10(5): PI65-69 :: ID: 11646
Abstract
Background:Prophylaxis of toxoplasmic encephalitis was performed with pyrimethamine in 6 patients with advanced HIV infection during combination therapy with protease inhibitors.Material/Methods: Steady-state plasma pyrimethamine (PYR) levels were measured by gas chromatography. Protease inhibitor plasma concentrations were analyzed trough concentration by high pressure liquid chromatography. During a treatment period of 22I13 months a total of 93 samples from 6 patients were investigated, containing pyrimethamine and protease inhibitors.Results: The mean pyrimethamine concentration was 1.108±459 ng/ml with a dosage of 37.5 mg/d and 1, 685±665 ng/ml with 50 mg/d. With the simultaneous use of indinavir (IDV), a mean pyrimethamine concentration of 2.165±I273 ng/ml was found, significantly higher than in combination with saquinavir (SQV) and ritonavir (RTV) (1.192±178 ng/ml) or saquinavir and nelfinavir (NLV) (1.117±173 ng/ml). This effect was not considered clinically significant. Drug monitoring of protease inhibitors revealed a wide range of protease inhibitor levels.Conclusions: The statistically significant lower PYR concentrations with the SQV + RTV or SQV + NLV comedication in comparison to comedication with IDV were not considered clinically significant. Therapeutic drug monitoring of PYR and PI plasma levels can be recommended in patients during therapy with both PYR and PI, especially during therapy with a double PI regimen.
Keywords: Antiretroviral Therapy, Highly Active, Chromatography, Gas, Chromatography, High Pressure Liquid, Encephalitis - prevention & control, HIV Infections - drug therapy, Protease Inhibitors - pharmacology, Pyrimethamine - pharmacology, Sensitivity and Specificity, Time Factors, Antiretroviral Therapy, Highly Active, Chromatography, Gas, Chromatography, High Pressure Liquid, Encephalitis - prevention & control, HIV Infections - drug therapy, Protease Inhibitors - pharmacology, Pyrimethamine - pharmacology, Sensitivity and Specificity, Time Factors
554 9
Editorial
01 June 2023 : Editorial
Editorial: Infectious Disease Surveillance Using Artificial Intelligence (AI) and its Role in Epidemic and Pandemic PreparednessDOI: 10.12659/MSM.941209
Med Sci Monit 2023; 29:e941209
In Press
05 Jun 2023 : Clinical Research
Comparison of Texture and Color Enhancement Imaging with White Light Imaging in 52 Patients with Short-Segm...Med Sci Monit In Press; DOI: 10.12659/MSM.940249
05 Jun 2023 : Laboratory Research
Comparison of Composite Resin (Duo-Shade) Shade Guide with Vita Ceramic Shades Before and After Chemical an...Med Sci Monit In Press; DOI: 10.12659/MSM.940949
02 Jun 2023 : Database Analysis
The COVID-19 Crisis and the Incidence of Alcohol-Related Deaths in PolandMed Sci Monit In Press; DOI: 10.12659/MSM.940904
01 Jun 2023 : Clinical Research
Root Canal Numbers and Configurations in 1080 Permanent Canine Teeth in 270 Saudi Subjects Using Cone-Beam ...Med Sci Monit In Press; DOI: 10.12659/MSM.940472
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952